Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
Early and effective glycemic control can prevent or delay the complications associated with type 2 diabetes (T2D). The benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs) are becoming increasingly recognized and they now feature prominently in international T2D treatment recommendations...
Main Authors: | Baptist Gallwitz, Francesco Giorgino |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.645507/full |
Similar Items
-
Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
by: Juris J. Meier, et al.
Published: (2021-09-01) -
Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01) -
Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
by: Juris J. Meier
Published: (2021-06-01) -
Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
by: Pearson S, et al.
Published: (2019-12-01) -
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
by: Michael A. Nauck, et al.
Published: (2021-03-01)